Clinical Trials

Phase 4 Active not recruiting

Urinary Bladder Neoplasms

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT07047118 2026-04-21

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

138 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03967977 2026-04-17

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Carcinoma, Transitional Cell

NCT04076059 2026-04-17

China ARCHES

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT05794906 2026-04-17

ARASTEP

985 enrolled

Biochemically Recurrent Prostate Cancer

NCT06052306 2026-04-17

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

232 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06545942 2026-04-17

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06451614 2026-04-16

HYDROSPACE

Phase NA Active not recruiting

230 enrolled

Prostatic Neoplasms

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Phase 4 Active not recruiting

Urinary Bladder Neoplasms

NCT04597125 2026-04-15

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

654 enrolled

Phase NA Active not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04905069 2026-04-15

SABRE

500 enrolled

Neoplasms, Prostatic Neoplasms

NCT06010914 2026-04-15

DADOX

100 enrolled

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07236112 2026-04-15

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04122976 2026-04-14

DAROL

805 enrolled

Prostatic Neoplasms

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT01946204 2026-04-13

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02123758 2026-04-13

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02365597 2026-04-13

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT02531516 2026-04-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT02592317 2026-04-13

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

23 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts

Urothelial Cancer

NCT03431350 2026-04-13

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT03523442 2026-04-13

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

19 enrolled

Prostatic Neoplasms

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03767244 2026-04-13

PROTEUS

2,517 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT04108208 2026-04-13

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

75 enrolled 9 charts

Prostatic Neoplasms

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 2 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04557059 2026-04-13

PRIMORDIUM

693 enrolled

Prostatic Neoplasms

NCT04577833 2026-04-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04640623 2026-04-13

SunRISe-1

220 enrolled 2 FDA

Urinary Bladder Neoplasms

NCT04644770 2026-04-13

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

144 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04658862 2026-04-13

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT04662580 2026-04-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT04898634 2026-04-13

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

216 enrolled

Prostatic Neoplasms

NCT05567185 2026-04-13

TAR-210

5 enrolled

Phase NA Active not recruiting

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT05683691 2026-04-13

VAPOR 2

400 enrolled

Prostatic Neoplasms

NCT05714202 2026-04-13

SunRISe-3

1,135 enrolled

Urinary Bladder Neoplasms

NCT05849298 2026-04-13

PSMACare

49 enrolled

Prostatic Neoplasms

NCT05901649 2026-04-13

ArtemisPRO

504 enrolled

Metastatic Hormone-sensitive Prostate Cancer

NCT06211764 2026-04-13

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06238479 2026-04-13

EXCEED

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

490 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06874114 2026-04-13

RE-ENGAGE

700 enrolled